Audit: QRS - Empagliflozin for Health & Longevity

Audit conducted on 29/08/2026 20:59 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every protocol cell, time-to-effect cell, gate item, tier item, marker row and qualitative item traces to a specific ER passage.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Speculative-tier items (“Slowed biological ageing”, “Blunting of training adaptations”) carry the ER’s own speculative framing; “lower recorded rate of dementia” retains the ER’s hedging word “recorded”.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications retain their ER force (“Type 1 diabetes without specialist ketone monitoring”, “Second trimester onward in pregnancy; breastfeeding”).
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come from the ER’s “Populations who should avoid Empagliflozin” list; Key Interactions from the ER’s interaction bullets; no Benefit- or Risk-Modifying Factor is repurposed.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT identifiers, expert names or brand names appear anywhere in the QRS; named example drugs (furosemide, glimepiride, ibuprofen, lithium, probenecid) all come from the ER’s interaction bullets.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind are present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Phrasing is lifted or condensed directly from the ER’s own sober, non-promotional register.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Tiered benefits and risks, concrete monitoring targets and decision gates give the reader an actionable, balanced picture.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Protocol cells describe trial dosing (“Trial dose, with or without diabetes”) rather than issuing instructions.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperatives; content is stated descriptively throughout, with the footer disclaimer retained.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No “should”, “recommended” or “advised” formulations occur.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person address anywhere in the document.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Plain phrasings are used where possible (“loss of kidney filtering”, “genital yeast infections”, “acute filtration drop on starting”); the residual technical terms are biomarker names required by the Monitoring table.
2.8	Information is presented in a concise and very compact manner	🟢	Gate items, tier items and marker cells are reduced to short noun phrases with mechanisms and mitigations stripped.
2.9	It DOES NOT address the reader directly	🟢	Confirmed — no direct address.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Functional monitoring ranges, ketone self-testing and the fasting/low-carbohydrate hazard are surfaced as the priority material.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	A 10-marker monitoring panel with a baseline/4-week/6-month cadence assumes a reader willing to execute it.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Content depth and monitoring burden exceed general-population framing.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-a-glance closes with “The ageing claim rests on mice”, and the ketoacidosis/fasting/low-carbohydrate interaction is elevated in both the gates and the qualitative list — precisely the audience-specific signal.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	The string “anti-aging” does not appear; the header and at-a-glance use “Longevity” and “ageing”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	“Tablet”, “hospitalizations”, “ketoacidosis”, “volume depletion” and the marker names are formal; the plainer at-a-glance wording mirrors the ER’s own Conclusion and Motivation phrasing as required by item 7.4.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed labels verified verbatim at lines 446, 489, 531, 560, 574, 596, 622, 626–628, 780 and in both tier lists.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	Diff of variable names against the template shows full coverage; the template’s marker_#_* and qualitative_item_# placeholders are expanded to marker_1..10_* and qualitative_item_1..6.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Diff of the QRS head/CSS block against the template is identical except for the title; the website="evidence_review", website="audit" and website="full_review" spans, the footer disclaimer and all structural comments are byte-identical to the template.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section that feeds the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol labels “Standard cardiorenal dose”, “Glycaemic escalation” and “Time of day” are verbatim from the ER Therapeutic Protocol bullets; all ten Monitoring marker names are verbatim from the ER biomarker table.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Time-to-effect labels (“Heart-failure benefit”, “Kidney-slope benefit”, “Blood pressure and weight”) are taken literally from the ER Practical Considerations time-to-effect bullet.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Grep for tier and warning emoji returns zero matches; the ER’s “⚠️ Conflicted” markers are correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	The template’s one-page layout is unmodified and every section is condensed to the minimum consistent with the completeness required by items 8.2, 9.2, 12.2, 13.2, 14.2 and 15.2 — gate items are bare noun phrases, marker “Why” cells are ≤ 45 characters, and no ER elaboration, mechanism or mitigation text is carried over.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after <!doctype html> on line 1 and before the template comment on line 16.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is repeated in the rendered body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, and it contains a colon requiring it.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: empagliflozin_2026-0829-1747_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0829-2011.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9: qrs_filename: empagliflozin_2026-0829-1747_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all eleven keys; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: Empagliflozin for Health & Longevity - Quick Reference Sheet.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: Empagliflozin for Health & Longevity.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: 08/29/2026, matching qrs_creation_date: 2026-0829-2011.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: Opus 5.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header block matches the template exactly; the ER’s “Also known as: Jardiance, BI 10773” line is correctly absent.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Lines 434–438 track the ER Conclusion’s structure: what it does, the smaller gains, the costs, and the limit of the ageing claim.
7.2	[at_a_glance] is no longer than 60 words	🟢	55 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to a distinct sentence in the ER Conclusion (lines 529–533).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “ketoacidosis” is rendered as “dangerous blood acid”, “eGFR decline” as “loss of kidney filtering”, “SGLT2 inhibition” as “flushes sugar out in the urine”.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years or sample sizes appear.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No hazard ratios, percentages or confidence intervals appear.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seven items derive from the “Populations who should avoid Empagliflozin” list at ER lines 358–366.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All seven ER avoid-list entries are present, in ER order, with none added or omitted.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Lines 563–569, seven discrete <li> elements.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s trailing rationales (“the ketoacidosis excess is dose-dependent and substantial”, “below this threshold there is no established benefit”, “kidney development in the fetus is the concern”) are all stripped.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	The eGFR threshold (20 mL/min/1.73 m²), the systolic threshold (100 mmHg), the pregnancy window (“second trimester onward”) and the infection frequency (“≥ 3 a year”) are all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in its avoid list.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER identifies seven such populations and the section is correspondingly populated, not empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All ten items derive from the ER interaction bullets at lines 338–356.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All ten ER interaction bullets are present in ER order; none duplicates a contraindication (the ER distinguishes an “unmodifiable ketogenic diet” as a contraindication from ketogenic eating as an interaction).
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Lines 577–586, ten discrete <li> elements.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every ER “Caution./Monitor.” classifier, mechanism sentence and “Mitigation:” clause is stripped; only the interacting agent or exposure remains.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Named example drugs are retained and trimmed rather than dropped: furosemide/hydrochlorothiazide, glimepiride/gliclazide, ibuprofen, caffeine.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in its interaction bullets.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER identifies ten such interactions and the section is correspondingly populated, not empty.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three action cells derive from the ER Therapeutic Protocol bullets at lines 392–396.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Standard dose, dose escalation and dose timing are the ER’s own first three bullets and the only directly executable ones; the remaining bullets are contextual (guideline positioning, genetics, combination context).
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER provides thirteen protocol bullets, so all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	Lines 450–485; all nine cells carry ER-derived content with no placeholder text remaining.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Heart-failure benefit, kidney-slope benefit, and blood pressure/weight — the three benefit-linked timelines in the ER Practical Considerations time-to-effect bullet (line 453).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Order matches the ER’s High-tier benefit ordering: heart failure/cardiovascular death first, kidney filtering second, blood pressure and weight third.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER provides four distinct time-to-effect aspects, so all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	Lines 495–524; all nine cells carry ER-derived content with no placeholder text remaining.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All twelve benefit facts map one-to-one to the ER Expected Benefits sub-headings at lines 150–220.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated at lines 533–553.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Every ER “Magnitude:” paragraph and trailing qualifier (“Without Hypoglycaemia”, “Without Reflex Tachycardia”, “and Rising Haemoglobin”) is stripped to the bare fact.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefits item.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers have items in the ER, so no span needs hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All eleven risk facts map one-to-one to the ER sub-headings at lines 244–314.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated at lines 598–616.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Every ER “Magnitude:” paragraph and the “⚠️ Conflicted” marker are stripped; items are bare noun phrases.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risks item.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers have items in the ER, so no span needs hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	The table derives from the ER Monitoring Protocol & Defining Success biomarker table at lines 483–494.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All ten ER biomarkers are present in ER order: eGFR, UACR, serum potassium, serum sodium, serum magnesium, HbA1c, serum uric acid, haematocrit, blood ketones, blood pressure seated and standing.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 773 reproduces the ER cadence at line 481: baseline, 4 weeks, 2 and 4 weeks for blood pressure, then 6-monthly with HbA1c and uric acid annually.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All six items derive from the ER qualitative-marker list at lines 498–503.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER qualitative markers are present in ER order: thirst/dry mouth, light-headedness on standing, night-time urination, genital symptoms, exercise tolerance, and the nausea/abdominal pain/rapid breathing cluster.

Issues 29/08/2026 20:59

Pass rate 100.00%. No issues found.

Issues 29/08/2026 20:50

1. 1.3 — NSAID caution broadened beyond ER: The Key Interactions item at line 579 reads “Non-steroidal anti-inflammatories (ibuprofen)” while the ER bullet is scoped to “Over-the-counter non-steroidal anti-inflammatories” (ER line 342), extending the caution to prescription agents the ER did not address; the very next item retains “Over-the-counter”, so the omission is inconsistent rather than budget-driven.
2. 9.5 — Thiazide example drug dropped: Line 577 preserves only “(furosemide, torasemide)”, both loop diuretics, dropping hydrochlorothiazide from the ER’s list (ER line 338) and leaving the co-named thiazide class with no example drug for a reader to match against.

Fixes 29/08/2026 20:50

1. 1.3 — NSAID caution rescoped to ER wording: Restored the ER’s scope qualifier on the Key Interactions item, changing “Non-steroidal anti-inflammatories (ibuprofen)” to “Over-the-counter non-steroidal anti-inflammatories (ibuprofen)”.
2. 9.5 — Thiazide example drug restored: Swapped the second loop-diuretic example for the missing thiazide, changing “(furosemide, torasemide)” to “(furosemide, hydrochlorothiazide)” so both named classes carry an example within the one-page budget.

Issues 29/08/2026 20:43

1. 1.3 — Hypotension contraindication narrowed: The contraindication at line 568, “Symptomatic or persistent systolic below 100 mmHg”, collapses the ER’s two independent criteria (ER line 365: “Symptomatic low blood pressure, or systolic pressure persistently below 100 mmHg”) into one, so symptomatic hypotension above 100 mmHg is no longer captured.

Fixes 29/08/2026 20:43

1. 1.3 — Hypotension contraindication restored: Changed the contraindication from “Symptomatic or persistent systolic below 100 mmHg” to “Symptomatic low blood pressure; systolic persistently below 100 mmHg”, restoring the ER’s two independent criteria.

Issues 29/08/2026 20:37

1. 11.4 — Time-to-effect sub restates value: [time_2_sub] at line 512 reads “Takes months to become visible”, which merely repeats [time_2_value] “Months” at line 509 and contributes no additional ER-derived content.

Fixes 29/08/2026 20:37

1. 11.4 — Time-to-effect sub restates value: Replaced [time_2_sub] “Takes months to become visible” with “Slower year-on-year decline in filtration”, so the sub carries a distinct ER fact (ER line 160) instead of repeating [time_2_value] “Months”.

Issues 29/08/2026 20:26

1. 4.5 — Content overruns one A4 page: Against a print budget of roughly 775 pt (A4 less the 12 mm sheet padding) the rendered content totals approximately 1,420 pt, dominated by the Monitoring table at ~372 pt (lines 630–784, where most Target and Why cells wrap to two lines) and the decision gates at ~284 pt (lines 559–597, with 13 wrapped contraindication lines and 17 wrapped interaction lines); no per-section condensation was applied to bring the sheet within the one-page budget.

Fixes 29/08/2026 20:26

1. 4.5 — Monitoring table condensed: Tightened twelve Target and Why cells so that eight of the ten biomarker rows now render on a single line instead of two (e.g. “Tracks the expected initial dip and the long-term slope” → “Detects the initial dip; tracks the slope”); the table body drops from 19 wrapped lines to 12. All ten ER biomarkers are retained.
2. 4.5 — Contraindication items shortened: Trimmed all seven stop items to their key fact while preserving every threshold and qualifier, e.g. “Recurrent genital or urinary tract infection (≥ 3 culture-proven episodes in 12 months)” → “Recurrent genital or urinary infection (≥ 3 a year)”.
3. 4.5 — Key Interaction items shortened: Trimmed the ten caution items and pared the example-drug lists to the shortest set that still names the class, e.g. “Over-the-counter diuretic and stimulant preparations (caffeine tablets, herbal diuretic blends)” → “Over-the-counter diuretics and stimulants (caffeine)”; the gate drops from 17 wrapped lines to 13.
4. 4.5 — Protocol sub-lines cut to one line: All three action sub-lines reduced from two rendered lines to one, e.g. “Where blood-sugar lowering is the goal and 10 mg is insufficient; adds infection risk” → “Adds glucose-lowering and infection risk”.
5. 4.5 — Benefit and Risk tiers tightened: Removed redundant qualifiers from the High tiers so the risks line falls from three rendered lines to two (“ketoacidosis, including at normal blood sugar” → “ketoacidosis at normal blood sugar”; “acute drop in estimated filtration rate on starting” → “acute filtration drop on starting”).
6. 4.5 — Monitoring cadence compressed: Shortened the cadence sentence from 195 to 173 characters by replacing “Baseline before the first dose” with “Baseline”, leaving the schedule itself unchanged.

Issues 29/08/2026 20:17

1. 4.5 — Sheet overflows one A4 page: The Monitoring “why” cells (QRS lines 655–787) and all six Qualitative Assessment items (lines 807–841) are transcribed verbatim from ER lines 485–503 rather than condensed to the per-section budget, and two Protocol subs plus the recurrent-infection contraindication run long; at the print width of 703 px the sheet renders to roughly two A4 pages.

Fixes 29/08/2026 20:17

1. 4.5 — Monitoring “why” cells condensed: All ten marker_#_why entries were shortened from the ER’s verbatim “Why Measure It?” wording to single-clause statements (e.g. “Detects the expected initial dip and tracks the long-term slope that the drug is meant to flatten” → “Tracks the expected initial dip and the long-term slope”).
2. 4.5 — Monitoring targets trimmed: marker_1_target reduced to “≥ 90 mL/min/1.73 m²; trend matters more than the absolute value” and marker_10_target to “< 120/80 mmHg seated; < 20 mmHg systolic drop on standing”, dropping redundant prose while keeping both thresholds.
3. 4.5 — Qualitative items shortened: All six qualitative_item_# entries were tightened to one rendered line each (e.g. “…treated early rather than tolerated to the point of discontinuation” → “…treated early rather than tolerated”).
4. 4.5 — Protocol subs tightened: action_1_sub and action_2_sub were cut to a single line each (“The dose used in the heart-failure and kidney trials, irrespective of diabetes status” → “Used in the heart-failure and kidney trials, with or without diabetes”).
5. 4.5 — Contraindication qualifier compressed: The recurrent-infection item now reads “(≥ 3 culture-proven episodes in 12 months)” instead of spelling the window out in words, preserving the threshold in less space.
6. 4.5 — Benefits and cadence trimmed: Dropped the redundant “without low-blood-sugar episodes” qualifier from benefits_high and collapsed the repeated test list in monitoring_cadence to “then all three every 6 months”.